The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Metalloproteinases and their inhibitors in tumor angiogenesis
Open accessAbstract
Angiogenesis is the process by which new blood vessels are formed from preexisting vasculature. It is an essential feature of the female reproductive cycle, embryonic development and wound repair. Angiogenesis has also been identified as a causal or contributing factor in several pathologies, including cancer, where it is a rate‐limiting step during tumor progression. Matrix metalloproteinases (MMPs) are a family of soluble and membrane‐anchored proteolytic enzymes that can degrade components of the extracellular matrix (ECM) as well as a growing number of modulators of cell function. Several of the MMPs, in particular the gelatinases and membrane‐type 1 MMP (MT1‐MMP), have been linked to angiogenesis. Potential roles for these proteases during the angiogenic process include degradation of the basement membrane and perivascular ECM components, unmasking of cryptic biologically relevant sites in ECM components, modulation of angiogenic factors and production of endogenous angiogenic inhibitors. This review brings together what is currently known about the functions of the MMPs and the closely related ADAM (a d isintegrin a nd m etalloproteinase domain) and ADAMTS (a d isintegrin a nd m etalloproteinase with t hrombo s pondin motifs) families in angiogenesis and considers how this information might be useful in manipulation of the angiogenic process, with a view to constraining tumor progression. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
A matrix metalloproteinase expressed on the surface of invasive tumour cells
Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., & Seiki, M. (1994) · Nature · doi:10.1038/370061a0 · Cited by 2,551
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Yu, Q., & Stamenkovic, I. (2000) · PubMed · Cited by 1,995
Cited by
Matrix metalloproteinases and tumor metastasis
Deryugina, E. I., & Quigley, J. P. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7886-9 · Cited by 1,960
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
Brew, K., & Nagase, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.01.003 · Cited by 1,381
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Copper in diseases and treatments, and copper‐based anticancer strategies
Tisato, F., Marzano, C., Porchia, M., Pellei, M., & Santini, C. (2010) · Medicinal Research Reviews · doi:10.1002/med.20174 · Cited by 797
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease
Wang, X., & Khalil, R. A. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.08.002 · Cited by 754
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease
Raffetto, J. D., & Khalil, R. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.004 · Cited by 752
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review
Riaz, M., Riaz, M., Zhang, X., Lin, C., Wong, K., Chen, X., Zhang, G., Lu, A., & Yang, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010195 · Cited by 509
Cancer and the tumor microenvironment: a review of an essential relationship
Mbeunkui, F., & Johann, D. J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0881-9 · Cited by 487
Smith, S. D., Dunk, C. E., Aplin, J. D., Harris, L. K., & Jones, R. L. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080995 · Cited by 471
Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10
Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., & Olson, E. N. (2006) · Cell · doi:10.1016/j.cell.2006.05.040 · Cited by 453
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead
van Hinsbergh, V. W. M., & Koolwijk, P. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm102 · Cited by 420
Membrane-type matrix metalloproteinases: Their functions and regulations
Itoh, Y. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.03.004 · Cited by 401
Assessment of Gelatinases (MMP-2 and MMP-9) by Gelatin Zymography
Toth, M., Sohail, A., & Fridman, R. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-854-2_8 · Cited by 395
Pericellular Proteases in Angiogenesis and Vasculogenesis
van Hinsbergh, V. W. M., Engelse, M. A., & Quax, P. H. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000209518.58252.17 · Cited by 389
Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice
Otsuka, M., Zheng, M., Hayashi, M., Lee, J.-D., Yoshino, O., Lin, S., & Han, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33680 · Cited by 329
Gueders, M. M., Foidart, J.-M., Noel, A., & Cataldo, D. D. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.082 · Cited by 322
Ries, C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1457-3 · Cited by 294
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A., & Cataldo, D. (2008) · Biochimie · doi:10.1016/j.biochi.2007.08.008 · Cited by 266
Recent advances in MMP inhibitor design
Fisher, J. F., & Mobashery, S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7894-9 · Cited by 215
Sorsby fundus dystrophy—A review of pathology and disease mechanisms
Christensen, D. R. G., Brown, F. E., Cree, A. J., Ratnayaka, J. A., & Lotery, A. J. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.08.014 · Cited by 60
Metadata
- Authors
- Handsley, M. M., & Edwards, D. R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-02-23
- Volume
- 115
- Issue
- 6
- Pages
- 849-860
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1973857272
- Cited by
- 307
- References
- 167
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.